It is a prime concern of Evotec that all relevant target groups receive the same information at the same time. This implies communicating in both English and German.


Here you will find the most recent corporate news, ad hoc releases and other announcements of our Company.

TODO

Subscribe to RSS

Learn more

News

Hamburg, Germany

Evotec SE reports H1 2025 results: Strong progress on strategy execution

Evotec SE today announced financial results for H1 2025, demonstrating clear progress in the implementation of its new strategy for sustainable and profitable growth; highlighting Just – Evotec Biologics’ strong growth as it transitions to an …

Learn more

News

Hamburg, Germany

Evotec SE to announce first half-year results 2025 on 13 August 2025

Evotec SE will announce its half-year interim report for the first six months of 2025 on Wednesday, 13 August 2025.

Learn more

News

Hamburg, Germany

Evotec and Sandoz evolve their strategic partnership and agree on potential sale of Just – Evotec Biologics Toulouse site

Evotec SE today announced the signing of a non-binding agreement with Sandoz AG regarding the potential sale of Just – Evotec Biologics EU...

Learn more

Ad Hoc

Hamburg, Germany

Ad hoc: Evotec SE and Sandoz AG planning potential sale of Just – Evotec Biologics Toulouse site

Hamburg, Germany – Evotec SE announces the signing of a non-binding agreement with Sandoz AG regarding the potential sale of Just – Evotec Biologics EU in Toulouse, France, for a consideration of about US$ 300 m in cash.

Learn more

News

Hamburg, Germany

Evotec adjusts revenue guidance and confirms profit guidance anticipating a more profitable revenue mix

Evotec SE today announced that it has updated its revenue guidance for the fiscal year 2025. R&D and adjusted EBITDA related guidance elements remain unaffected.

Learn more

Ad Hoc

Hamburg, Germany

Ad hoc: Evotec SE adjusts revenue guidance while confirming profit guidance

Evotec SE announces that it has updated its revenue guidance for the fiscal year 2025. Guidance on R&D expenses and adjusted EBITDA remains unchanged.

Learn more

News

Hamburg, Germany

Evotec joins NURTuRE-AKI consortium to gain multi-omics-based molecular understanding of acute kidney injury

Evotec SE announced that it has joined the NURTuRE AKI consortium for establishing a patient cohort for acute kidney injury (AKI), NURTuRE AKI.

Learn more

News

Hamburg, Germany

Evotec SE: Results of the Annual General Meeting 2025

Evotec SE today announced that its shareholders approved most of the proposals the Company’s Management put to vote at the Company’s Annual General Meeting 2025 with great majority.

Learn more

News

Hamburg, Germany

Evotec response to the FDA’s “Roadmap to Reducing Animal Testing in Preclinical Safety Studies”

Evotec welcomes the FDA's “Roadmap to Reducing Animal Testing in Preclinical Safety Studies” which is aligned with our 30+ year commitment to ethics and the principles of 3-Rs (Replacement, Reduction and Refinement). As part of this commitment …

Learn more

News

Hamburg, Germany

Evotec receives $ 2.5 m grant to generate next generation tuberculosis treatments

Evotec SE announced the award of a US$ 2.5 m grant from The Gates Foundation (GF) to support the development of next-generation treatment regimens for tuberculosis (TB).

Learn more

News

Hamburg, Germany

Evotec SE reports Q1 2025 results: Paving the way for 2025 growth in soft market environment

Evotec SE today announced its financial results for Q1 2025, highlighting progress in strategic partnerships and implementation of measures to generate sustainable profitable growth.

Learn more

News

Hamburg, Germany

Evotec SE to announce results for the first quarter 2025 on 6 May 2025

Evotec SE will announce its interim statement for the first quarter of 2025 on Tuesday, 6 May 2025.

Learn more

News

Hamburg, Germany

Evotec announces significant progress in strategic protein degradation collaboration with Bristol Myers Squibb

Evotec SE announced further significant progress of the Company’s strategic research collaboration with Bristol Myers Squibb relating to building a high value molecular glue-based pipeline for unmet medical needs.

Learn more

News

Hamburg, Germany

Evotec SE unveils new strategy and provides 2025 guidance

Evotec SE today announced its financial results for FY 2024, provided guidance for FY 2025 and outlook for 2028 reflecting the path to sustainable profitable growth, following the completion of its strategic review process.

Learn more

News

Hamburg, Germany

Evotec Announces Key Progress in Neuroscience Collaboration with Bristol Myers Squibb

Evotec SE announced another major accomplishment in its long-standing neuroscience collaboration with Bristol Myers Squibb.

Learn more

News

Hamburg, Germany

Evotec announces change in Management Board

Evotec SE today announced that its Chief Financial Officer, Laetitia Rouxel, will step down from her role of Chief Financial Officer effective 28 February 2025 and leave the Company effective 31 March 2025 to pursue other opportunities.

Learn more

News

Hamburg, Germany

Evotec receives grant from Korean Government to develop novel antibody-based treatments for lung diseases Context

Evotec SE announced that, together with Yonsei University and the Korean biotech company Zymedi, it will receive a grant from the Korea Institute of Advanced Technology (KIAT). The KIAT grant will fund the development of first-in-class biologic …

Learn more

Don't Miss Our Latest Scientific Updates

Register your email to get latest news and insights straight to your inbox with our monthly newsletter. 

To complete your registration for our newsletter, please consent to us contacting you. 

All details on the processing of your personal data can be found in our Privacy Policy.

By submitting this form, you consent to allow Evotec to store and process the personal information you provided above to handle your enquiry.

Contact Us

info@evotec.com

+49 40 560 81 0

Follow Us

Evotec Logo White Logo cyprotex white footer Logo justevotec biologics white footer

©2024, All right reserved.